Ingalls & Snyder LLC Grows Position in Novartis AG (NYSE:NVS)
Ingalls & Snyder LLC Grows Position in Novartis AG (NYSE:NVS)
Ingalls & Snyder LLC raised its holdings in Novartis AG (NYSE:NVS – Get Rating) by 7.1% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 105,098 shares of the company's stock after acquiring an additional 6,961 shares during the period. Ingalls & Snyder LLC's holdings in Novartis were worth $9,222,000 at the end of the most recent reporting period.
英格尔斯-斯奈德有限责任公司在提交给美国证券交易委员会的最新文件中称，今年第一季度，该公司将其在诺华制药的持股比例提高了7.1%。该机构投资者持有105,098股该公司股票，在此期间又购买了6,961股。在最近一次报告期结束时，Ingalls&Snyder LLC持有的诺华股份价值9,222,000美元。
Several other institutional investors and hedge funds have also recently modified their holdings of the business. Dimensional Fund Advisors LP increased its position in shares of Novartis by 35.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,870,136 shares of the company's stock valued at $338,521,000 after purchasing an additional 1,003,235 shares during the last quarter. Cullen Capital Management LLC increased its position in shares of Novartis by 17.6% during the 1st quarter. Cullen Capital Management LLC now owns 3,295,271 shares of the company's stock valued at $289,160,000 after purchasing an additional 492,643 shares during the last quarter. Fisher Asset Management LLC increased its position in shares of Novartis by 4.7% during the 1st quarter. Fisher Asset Management LLC now owns 10,871,033 shares of the company's stock valued at $953,933,000 after purchasing an additional 486,367 shares during the last quarter. Renaissance Technologies LLC grew its position in Novartis by 12.7% during the 4th quarter. Renaissance Technologies LLC now owns 3,727,570 shares of the company's stock worth $326,051,000 after acquiring an additional 420,333 shares during the last quarter. Finally, Boston Partners grew its position in Novartis by 6.7% during the 4th quarter. Boston Partners now owns 4,677,403 shares of the company's stock worth $409,194,000 after acquiring an additional 292,854 shares during the last quarter. Hedge funds and other institutional investors own 9.40% of the company's stock.
其他几家机构投资者和对冲基金最近也调整了对该公司的持股。Dimension Fund Advisors LP在第四季度将其在诺华股票的持仓增加了35.0%。Dimension Fund Advisors LP现在拥有3870,136股该公司的股票，价值338,521,000美元，在上个季度又购买了1,003,235股。第一季度，库伦资本管理公司将其在诺华公司股票的持仓增加了17.6%。卡伦资本管理有限责任公司在上个季度额外购买了492,643股后，现在拥有3,295,271股该公司的股票，价值289,160,000美元。Fisher Asset Management LLC在第一季度将其在诺华股票的持仓增加了4.7%。Fisher Asset Management LLC在上个季度额外购买了486,367股后，现在拥有10,871,033股该公司股票，价值953,933,000美元。复兴技术有限责任公司在第四季度将其在诺华的头寸增加了12.7%。复兴科技有限责任公司在上个季度增持了420,333股后，现在拥有3,727,570股该公司股票，价值326,051,000美元。最后，波士顿合伙公司在第四季度将其在诺华的头寸增加了6.7%。波士顿合伙公司在上个季度增持了292,854股后，现在持有4677,403股该公司股票，价值409,194,000美元。对冲基金和其他机构投资者持有该公司9.40%的股份。
Analyst Ratings Changes
分析师评级发生变化
NVS has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft reduced their price target on Novartis from CHF 80 to CHF 75 in a research report on Wednesday, June 29th. Barclays raised their price target on Novartis from CHF 80 to CHF 85 in a research report on Thursday, April 14th. upgraded Novartis from a "hold" rating to a "buy" rating in a research report on Thursday, April 14th. UBS Group raised their price target on Novartis from CHF 85 to CHF 88 and gave the stock a "neutral" rating in a research report on Wednesday, April 27th. Finally, Oppenheimer lowered Novartis from an "outperform" rating to a "market perform" rating in a research report on Friday, June 3rd. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $87.33.
NVS一直是最近几份研究报告的主题。德意志银行Aktiengesellschaft在6月29日星期三的一份研究报告中将诺华的目标价从80瑞士法郎下调至75瑞士法郎。巴克莱在4月14日周四的一份研究报告中将诺华的目标价从80瑞士法郎上调至85瑞士法郎。在4月14日周四的一份研究报告中，将诺华的评级从持有上调至买入。瑞银集团在4月27日周三的一份研究报告中将诺华公司的目标价从85瑞士法郎上调至88瑞士法郎，并给予该股“中性”评级。最后，在6月3日星期五的一份研究报告中，奥本海默将诺华的评级从“跑赢大盘”下调至“市场表现”。两名投资分析师对该股的评级为卖出，八名分析师发布了持有评级，三名分析师给予了买入评级，一名分析师对该股给予了强烈的买入评级。根据MarketBeat.com的数据，该股目前的平均评级为持有，共识目标价为87.33美元。
Novartis Trading Up 0.4 %
诺华公司股价上涨0.4%
Novartis (NYSE:NVS – Get Rating) last released its earnings results on Monday, July 18th. The company reported $1.56 EPS for the quarter, beating analysts' consensus estimates of $1.52 by $0.04. The company had revenue of $12.78 billion during the quarter, compared to analysts' expectations of $12.78 billion. Novartis had a return on equity of 21.88% and a net margin of 44.31%. The firm's revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.64 EPS. Equities research analysts predict that Novartis AG will post 6.06 earnings per share for the current fiscal year.
诺华公司(纽约证券交易所代码：NVS-GET Rating)最近一次发布收益报告是在7月18日星期一。该公司公布本季度每股收益为1.56美元，比分析师普遍预期的1.52美元高出0.04美元。该公司当季营收为127.8亿美元，高于分析师预期的127.8亿美元。诺华的股本回报率为21.88%，净利润率为44.31%。与去年同期相比，该公司本季度的收入下降了1.4%。去年同一季度，该业务公布的每股收益为1.64美元。股票研究分析师预测，诺华制药本财年每股收益将达到6.06欧元。
About Novartis
诺华公司简介
(Get Rating)
(获取评级)
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.
诺华制药在全球研究、开发、制造和营销保健品。该公司通过两个部门运营，创新药品和Sandoz。创新药品部门为患者和医疗保健提供者提供处方药。它还提供眼科、神经科学、免疫学、肝科、皮肤科、呼吸科、心血管、肾脏和新陈代谢药物产品。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- Why Apple Could Be At All-Time Highs By Year End
- 免费获取StockNews.com关于诺华(Novartis)的研究报告
- MarketBeat：回顾中的一周8/1-8/5
- 如何利用高贝塔系数股票最大化你的投资利润
- 克罗诺斯集团(Cronos Group Inc.)营收上升，是时候收购了吗？
- Beyond Meat不是没有希望，而且它很便宜
- 苹果为何可能在年底创下历史新高
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
接受诺华日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对诺华和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。